Divalproex Sodium Tablet, Delayed Release
Product Images NDC 72162-2316

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 72162-2316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl721622316)

Label (Lbl721622316)
This text provides information about a medication in the form of enteric-coated, delayed-release tablets containing Divalproex Sodium equivalent to 2059 valproic acid 250 mg. The tablets are orange colored and imprinted with "797" on one side. It is recommended to store them at 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). The tablets should be kept in a tight, light-resistant container and out of reach of children. The medication is relabeled by Bryant Ranch Prepack, Inc and manufactured by Sun Pharmaceutical Industries Ltd. Pharmacist guidance is advised for dispensing with a Medication Guide available for patients. For detailed information, refer to the provided link.*
FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)
FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)
This text provides a visual representation of the reduction in CPS (Chronic Pain Syndrome) rate, comparing the effectiveness of DVPX treatment versus a placebo. The figure shows different percentages of patients experiencing improvement, no change, or worsening in their condition. The data includes percentages ranging from -100% to 100%, offering insights into the impact of the treatment on patients with chronic pain.*
FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)
FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)
This is a comparison chart showing the mean 4-week migraine rates for Placebo and DVPX (divalproex sodium) in Study 1 and Study 2. It presents data on the effectiveness of the two treatments in reducing migraine occurrences over a 4-week period.*
FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Spl-divalproex-structure (Spl Divalproex Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.